Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: Atemoyacin-B

Acta Pharmacologica Sinica

Volumn 20, Issue 5, 1999, Pages 435-439

  Fu, Li Wu ^a   Pan, Qi Chao ^a   Liang, Yong Ju ^a   Huang, Hong Bing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Annonaceous acetogenin; Apoptosis; Atemoyacin B; Bullatacin; Cultured tumor cells; Doxorubicin; Fura 2; Multiple drug resistance; Phytogenic antineoplastic agents; Vincristine

Indexed keywords

ACETOGENIN; ATEMOYACIN B; BULLATACIN; DOXORUBICIN; FURA 2 ACETOXYMETHYL ESTER; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG ACCUMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; SPECTROFLUOROMETRY; TUMOR CELL LINE;

4-BUTYROLACTONE; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FATTY ALCOHOLS; FURA-2; FURANS; HUMANS; KB CELLS; TUMOR CELLS, CULTURED;

EID: 0033008367     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995; 15: 331-6.
2. Pan QC, Tian H. Tumor multidrug resistance reversed by various Chinese herb principles. Chin Sci Bull 1995; 40: 1901-4.
3. Massart C, Gibassier J, Raoul M, Denais A, Maugendre S, Darcel F, et al. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in modullary thyroid carcinoma xenograft. Anticancer Drugs 1996; 7: 321-30.
4. Fu LW, Pan QC. The properties of compounds with reversing tumor multidrug resistance. Chin J Cancer 1996; 15: 475-7.
5. Alfonso D, Johnson HA, Colman-Saizarbitoria T, Presley CP, McCabe GP, McLaughlin JL. SARs of annonaceous acetogenins in rat liver mitochondria. Nat Toxins 1996; 4: 181-8.
6. Chen WS, Yao ZJ, Zhang YB, Xu YZ, Wu YL. Atemoyacin B: a new bis-tetrahydrofuranyl annonaceous acetogenin from Annona atemoya H. Chin J Chem 1995; 13: 263-6.
7. Morre DJ, de Cabo R, Farley C, Oberlies NH, McLaughlin JL. Mode of action of bullatacin, a potent antitumor acetogenin: inhibition of NADH oxidase activity of HeLa and HL-60, but not liver, plasma membranes. Life Sci 1995; 56: 3-13-8.
8. Zhang XH, Zhang FY, Ji XJ, Li ZY. Vincristine-resistant human KB cell line and mechanism of multidrug resistance. Acta Pharm Sin 1991; 29: 2-16-51.
9. Fu LW, Pan QC. A new method for the screening of the drug with multidrug resistance reversing activity by Fura 2-AM. Chin Pharm J 1995; 30 (11 Suppl): 109-11.
10. Carmichael J, DeGraff WG, Gazadar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987; 47: 913-6.
11. Kang Y, Perry RR. Modulatory effects of tamoxifen and recombinant human a-interferon on doxorubicin resistance. Cancer Res 1993; 53: 3010-5.
12. Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997; 11: 1180-6.
13. Oberlies NH, Croy VL, Harrison ML, McLaughlin JL. The annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Cancer Lett 1997; 115: 73-9.
14. Versantvoort CH, Broxterman HJ, Pinedo HM, de Vries EGE, Feller N, Kuiper CM, et al. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 1992; 52: 17-23.